To investigate the mechanism underlying the observed down-regulation of cFLIP proteins levels upon the inhibition of the mevalonate pathway with simvastatin, we first assessed cFLIP mRNA levels in A549 tumor cells treated with the statin (Figure 6E) at a dose that induces maximal sensitization to TRAIL (Figure 1A). The gene discussed is CFLAR; the disease is neoplasm.